IntraLinks Enhances Study Management Offering; Expands its Suite of SaaS-based Solutions for Clinical Operations

IntraLinks Enhances Study Management Offering; Expands its Suite of SaaS-based Solutions for Clinical Operations
 
NEW YORK, November 16, 2010 /PRNewswire-FirstCall/ --

- IntraLinks for Study Management Provides Unparalleled Automation and Insight Into Document-Centric Processes Throughout the Entire Clinical Trial Lifecycle

IntraLinks, a leading provider of critical information exchange solutions, today announced IntraLinks for Study Management, a secure, online platform for managing and monitoring all communication and activity with investigative sites and other outside parties during clinical trials from study start-up through study close-out. The new offering expands the full suite of IntraLinks' solutions for clinical operations, which accelerates business processes, cuts costs and reduces risks throughout the entire clinical trial lifecycle.

    IntraLinks for Study Management specifically helps to:

    - Centralize all study-related documents, communication and activity
      history in an organized, consistent and searchable fashion
    - Standardize and automate processes such as contract & budget
      negotiation, regulatory document distribution and collection and
      ongoing document exchange
    - Eliminate repetitive and redundant site data entry and document
      submission
    - Provide sites with a personalized view of tasks, requests and due
      dates, with reminder alerts and a secure communication channel to
      ensure timely site activation
    - Monitor process progress with real-time activity dashboards and meet
      regulatory compliance with detailed access reports and audit trails

IntraLinks, which is already used by the top 10 global pharmaceuticals, biotechs and Contract Research Organizations (CROs), also offers a collaborative platform for site recruitment and safety reporting as part of its suite of solutions. IntraLinks for Site Recruitment enables users to eliminate the redundancy and manual tasks related to feasibility survey creation, distribution and collection. IntraLinks for Safety Document Exchange provides a secure environment where safety teams can receive notifications, route them for review, and instantaneously distribute subsequent letters to all parties requiring notification in an intelligent, automated and auditable fashion.

"The clinical research community has trusted IntraLinks for over 10 years to securely exchange information and accelerate processes, while upholding quality and maintaining regulatory compliance," said Fahim Siddiqui, executive vice president, product & operations, IntraLinks. "IntraLinks for Study Management expands our offering and enables our customers to use us from start to finish for clinical trials, meeting a critical business need. For example, we estimate that companies can save two million dollars in study start-up costs and reduce cycle time by 50% for an average Phase III clinical trial when using IntraLinks instead of traditional paper-based methods of document distribution, collection and collaboration."

About IntraLinks

IntraLinks (NYSE: IL) is a leading global provider of Software-as-a-Service solutions for securely managing content, exchanging critical business information and collaborating within and among organizations. More than 1.3 million professionals in industries including financial services, pharmaceutical, biotechnology, consumer, energy, industrial, legal, insurance, real estate and technology, as well as government agencies, have utilized IntraLinks' easy-to-use, cloud-based solutions. IntraLinks users can accelerate information-intensive business processes and workflows, meet regulatory and risk management requirements and collaborate with customers, partners and counterparties in a secure, auditable and compliant manner. IntraLinks counts 800 of the Fortune 1000 as users. For more information, visit http://www.intralinks.com or http://blog.intralinks.com. You can also follow IntraLinks on Twitter at http://twitter.com/intralinks and Facebook at http://www.facebook.com/IntraLinks.

Media Contact: Radley Moss, IntraLinks, +1-212-543-7717, [email protected]


SOURCE IntraLinks Holdings, Inc.

 

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”